Request Consultation
search-icon
Download Videssa Guide

Provista Blog > Streamline the Diagnostic Process: Breast Cancer

Provista Blog

Streamline the Diagnostic Process: Breast Cancer

Posted by Provista Diagnostics on October 11, 2017
Share:     

Integrating Videssa® Breast into Clinical Practice

Videssa Breast is an ideal diagnostic complement to breast imaging – particularly when clinical assessments are challenging. For women with abnormal imaging findings, Videssa Breast can be used in the diagnostic workup to help support recommendations for further management and increase confidence in a patient's clinical course (results are not impacted by breast density). 

When Should Videssa Breast Be Considered?

Videssa Breast is designed to easily fit within existing clinical workflows. The Videssa Breast test result can be used along with a patient's clinical history and imaging results to determine the most appropriate plan for follow up care. Immediately following an abnormal or difficult-to-interpret mammogram, Videssa Breast can be incorporated as a "next step" in patient care – prior to additional diagnostic procedures – to help triage a woman to biopsy, additional imaging or six-month imaging surveillance. Videssa Breast can help identify patients who may warrant immediate follow-up versus those who can proceed with a "watchful waiting" approach. 

 

Gray Zone Image-Clinical Results Summary eBook-01.png

 

The "Next Step" After an Abnormal Mammogram

For women with abnormal imaging, it is not always clear whether to proceed with a biopsy, further diagnostic imaging or to "watch and wait" with six-month follow up imaging. When abnormal imaging arises (BI-RADS 3 or 4), the National Comprehensive Cancer Network (NCCN) guidelines recommend that BI-RADS 3 patients are followed every six months for two years, while BI-RADS 4 patients are recommended for biopsy. 

When the probability of breast cancer is low, avoiding putting women through benign biopsies (or additional imaging), can help reduce patient anxiety and healthcare costs. At the same time, monitoring these women closely is essential in case any anatomical changes occur that may be associated with breast cancer. Videssa Breast can provide additional guidance if there is a need for interventional procedures. 

Triage Women with Dense Breasts – A Clear Answer for Confident Action

4 BI-RADS CAtegories.png

For women with dense breasts, there is a greater chance of breast cancer being missed; therefore, patients are often left with anxiety, concern and no clear alternative solution. Currently no clinical guidelines recommend the use of supplemental imaging in women with dense breasts and there is a lack of consistency in recommendations from state to state, so "next steps" are not always clear. Integrating Videssa Breast into the current standard-of-care offers an alternative approach to breast cancer detection, not affected by breast density, to help navigate through the diagnostic process when imaging is limited and next steps are unclear. 

If a woman with abnormal imaging is also scored as with a breast density category "C" (heterogeneously dense) or "D" (extremely dense) on a mammogram, Videssa Breast can be utilized to help determine the need for supplemental imaging and/or biopsy.

 

Real-Time Clinically Actionable Test Results

Videssa Breast delivers real-time clinically actionable test results to help guide a patient through the diagnostic process when clinical assessment is challenging. Test results are reported as either:

  • Low Protein Signature: likely indicating the absence of breast cancer
  • High Protein Signature: may potentially indicate the presence of breast cancer

Key Takeaways

  • The timing of ordering Videssa Breast is most helpful immediately following an abnormal or difficult-to-interpret mammographic finding, prior to additional diagnostic procedures.
  • Women who receive a high protein signature test result will likely warrant additional imaging and/or a biopsy, while women who receive a low protein signature test result may not warrant immediate follow-up and may benefit from a "watch and wait" approach. 
clinical-breast-cancer-study
Provista Diagnostics

Provista Diagnostics

At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.